Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca
  1. Pubblicazioni

[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab

Articolo
Data di Pubblicazione:
2021
Abstract:
Background: Data regarding the role of positron emission tomography/computed tomography (PET/CT) to stage lymph nodes in patients receiving neoadjuvant immunotherapy before radical cystectomy are lacking. The aim of this study is to evaluate the role of PET/CT to predict the pathologic lymph node involvement (LNI) in patients with MIBC receiving neoadjuvant pembrolizumab within the PURE-01 trial (NCT02736266). Material and methods: Three courses of pembrolizumab were administered before radical cystectomy and extended pelvic lymph node dissection in clinical T2-4aN0M0 MIBC based on contrast-enhanced CT scan. LNI was also assessed with PET/CT before and after treatment. PET/CT results were compared with histopathological findings. The ability of baseline and post-therapy PET/CT to evaluate LNI was assessed, and univariate logistic regression analyses were performed. Results: From February 2017 to August 2019, a total of 108 patients and 105 patients had evaluable baseline and post-pembrolizumab scans, respectively. The sensitivity to detect LNI was 27% and 37.5% for pre- and post-pembrolizumab PET/CT, and specificity was 97% and 98%, respectively. In total, 4 of 7 patients (57%) showing baseline FDG-uptake had LNI vs. 11 of 101 (11%) with no baseline uptake. All but 1 of the 7 patients did not respond to pembrolizumab. Both pre- and post-pembrolizumab PET/CT significantly predicted LNI (P = 0.004 and P < 0.001) at univariate analyses. Our results warrant further validation in larger datasets. Conclusions: PET/CT performance does not justify its use in routine practice for cN0 MIBC. However, our preliminary data revealed opportunities for the use of baseline PET/CT, within clinical trials, to optimally select patients with MIBC who are best suited for neoadjuvant immunotherapy strategies. Validation in larger datasets, as well as a cost analysis, are needed.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Lymph node involvement; MIBC; Pembrolizumab; PET/CT
Elenco autori:
Marandino, L.; Capozza, A.; Bandini, M.; Raggi, D.; Fare, E.; Pederzoli, F.; Gallina, A.; Capitanio, U.; Bianchi, M.; Gandaglia, G.; Fossati, N.; Colecchia, M.; Giannatempo, P.; Serafini, G.; Padovano, B.; Salonia, A.; Briganti, A.; Montorsi, F.; Alessi, A.; Necchi, A.
Autori di Ateneo:
BRIGANTI ALBERTO
COLECCHIA MAURIZIO
GANDAGLIA GIORGIO
MONTORSI FRANCESCO
NECCHI ANDREA
SALONIA ANDREA
Link alla scheda completa:
https://iris.unisr.it/handle/20.500.11768/107642
Pubblicato in:
UROLOGIC ONCOLOGY
Journal
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.5.0.0